However, the potential for delaying or preventing the progression of T2DM in patients treated with GIP and GLP-1 remains uncertain, as there is currently no definitive evidence from human studies demonstrating that enhanced incretin activity directly affects -cell mass or alters the progressive loss of insulin secretory capacity in humans
Get GLP-1 Medications through PlushCare PlushCare is for the person who wants access to GLP-1s but would prefer to speak with a doctor without visiting one in person
STONE, R
A total of 484 patients with a mean duration of diabetes of 8.1 years were randomised to receive lixisenatide 20 g OD ( n = 323) or placebo ( n = 161) with a two-step dose increase, in combination with pioglitazone, for the main double-blind treatment period of 24 weeks, followed by a variable double-blind extension of at least 52 weeks
Great product I am happy with the results of this medication and with the Vitastin Clinic, which is very efficient and offers excellent treatment in every way
Diabetes 62 , 38283838 (2013)